Jade Biosciences, Inc. (NASDAQ:JBIO) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Jade Biosciences, Inc. (NASDAQ:JBIO) has received an average rating of “Moderate Buy” from the seven ratings firms that are presently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, five have given a buy rating and one has given a strong buy rating to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $24.00.

JBIO has been the topic of several research analyst reports. Lifesci Capital upgraded shares of Jade Biosciences to a “strong-buy” rating in a research note on Friday. Weiss Ratings reiterated a “sell (e+)” rating on shares of Jade Biosciences in a research report on Monday, December 29th. Wall Street Zen raised shares of Jade Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, November 15th. Guggenheim lifted their target price on shares of Jade Biosciences from $14.00 to $17.00 and gave the company a “buy” rating in a research note on Tuesday, November 18th. Finally, Stifel Nicolaus set a $40.00 price objective on Jade Biosciences in a research note on Friday.

Jade Biosciences Price Performance

Shares of NASDAQ JBIO opened at $14.05 on Friday. Jade Biosciences has a one year low of $6.57 and a one year high of $100.10. The firm’s 50 day simple moving average is $14.78 and its two-hundred day simple moving average is $11.92. The stock has a market capitalization of $692.81 million, a P/E ratio of -3.05 and a beta of 1.03.

Jade Biosciences (NASDAQ:JBIO) last posted its earnings results on Friday, March 6th. The company reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.34.

Institutional Investors Weigh In On Jade Biosciences

Large investors have recently bought and sold shares of the business. Invesco Ltd. lifted its holdings in shares of Jade Biosciences by 477.6% in the 4th quarter. Invesco Ltd. now owns 199,727 shares of the company’s stock worth $3,082,000 after acquiring an additional 165,151 shares during the last quarter. Ikarian Capital LLC bought a new stake in shares of Jade Biosciences during the 4th quarter worth approximately $4,629,000. Virtus Investment Advisers LLC purchased a new position in Jade Biosciences during the 4th quarter valued at $274,000. Opaleye Management Inc. purchased a new position in Jade Biosciences during the 4th quarter valued at $6,598,000. Finally, Millennium Management LLC bought a new position in Jade Biosciences in the 4th quarter valued at $969,000.

Jade Biosciences Company Profile

Jade Biosciences, Inc is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics for inflammatory skin diseases and chronic itch. Leveraging a small‐molecule platform, the company seeks to address significant unmet needs in dermatology by targeting key pathways involved in pruritus and skin inflammation. Its research efforts are centered on identifying and advancing molecules that can modulate receptor activity in the skin, with a goal of improving safety and efficacy compared to existing treatments.

The company’s lead programs are built around proprietary compounds designed to penetrate the epidermal barrier and selectively inhibit molecular drivers of itch and inflammation.